National Human Genome Research Institute (NHGRI)

genome.gov

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

203

Active

36

Phase 3

0

Total enrollment

240,826

Pipeline matrix

Showing 8 of 8 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
ManNAc3
Sirolimus2
MK-70752
AAV9-GLB11
Rituximab1
Methylprednisolone1
Prednisone1
Cysteamine1

Next readouts

  • 2026-06-25
  • 2027-11-30
  • 2028-01-01

Top conditions

  • Diabetes9
  • Healthy Volunteers7
  • Breast Cancer6
  • Genetic Disease5
  • Cancer5
  • Proteus Syndrome4
  • Hypertension4
  • Birth Defects4

Frequently asked questions about National Human Genome Research Institute (NHGRI)

How many clinical trials does National Human Genome Research Institute (NHGRI) have on ClinicalTrials.gov?
National Human Genome Research Institute (NHGRI) is listed as the lead sponsor on 203 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
How many of National Human Genome Research Institute (NHGRI)'s trials are in Phase 3?
0 of National Human Genome Research Institute (NHGRI)'s trials are in Phase 3, spread across 8 active drug programs.
What therapeutic areas does National Human Genome Research Institute (NHGRI) focus on?
National Human Genome Research Institute (NHGRI)'s most-studied conditions on ClinicalTrials.gov are Diabetes, Healthy Volunteers, Breast Cancer, Genetic Disease, Cancer.
When are National Human Genome Research Institute (NHGRI)'s next clinical trial readouts?
National Human Genome Research Institute (NHGRI) has 3 upcoming primary-completion readouts tracked here; the soonest is “MK-7075 (Miransertib) in Proteus Syndrome”, expected around 2026-06-25.